{"id":11774,"date":"2026-10-29T10:49:49","date_gmt":"2026-10-29T02:49:49","guid":{"rendered":"https:\/\/regask.com\/?p=11774"},"modified":"2026-10-30T11:59:34","modified_gmt":"2026-10-30T03:59:34","slug":"biowissenschaften-im-oktober-2026-schnellere-studien-gefalschte-peptide-und-ki-regelwerke","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/","title":{"rendered":"Life Sciences im Oktober 2026: Schnellere Studien, gef\u00e4lschtes Peptid\u2026"},"content":{"rendered":"<p><span class=\"TextRun SCXW241937270 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW241937270 BCX0\">From mid-September to mid-October 2026, life sciences regulators made one thing plain: they are working to speed up legitimate innovation and shut down illegitimate supply at the same time. Our Trends Radar tracked official developments across all nine <\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW241937270 BCX0\">RegASK<\/span><span class=\"NormalTextRun SCXW241937270 BCX0\"> regions, and three trends stood out. First, regulators are racing to get clinical trials started sooner, with new pilots and pathways in the U.S., Europe, the U.K., Saudi <\/span><span class=\"NormalTextRun SCXW241937270 BCX0\">Arabia<\/span><span class=\"NormalTextRun SCXW241937270 BCX0\"> and Brazil. Second, authorities on 6 continents moved against counterfeit and unapproved weight-loss peptides, <\/span><span class=\"NormalTextRun SCXW241937270 BCX0\">escalating<\/span><span class=\"NormalTextRun SCXW241937270 BCX0\"> warnings to bans, seizures and criminal charges. Third, adaptive and generative AI in medical devices is getting its first dedicated rulebooks. For global teams, the gap between the fastest and slowest regulatory systems, and between the legal and illegal market, is becoming a strategic <\/span><span class=\"NormalTextRun SCXW241937270 BCX0\">variable<\/span><span class=\"NormalTextRun SCXW241937270 BCX0\">.<\/span><\/span><span class=\"EOP Selected SCXW241937270 BCX0\" data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:300}\">\u00a0<\/span><\/p>\n\t<div id=\"gap-1842791789\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1842791789 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h3><span class=\"TextRun MacChromeBold SCXW137401277 BCX0\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW137401277 BCX0\" data-ccp-parastyle=\"heading 1\">The Race to Start Clinical Trials <\/span><\/span><span class=\"TextRun MacChromeBold SCXW137401277 BCX0\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW137401277 BCX0\" data-ccp-parastyle=\"heading 1\">Sooner<\/span><\/span><span class=\"EOP Selected SCXW137401277 BCX0\" data-ccp-props=\"{&quot;335559739&quot;:140}\">\u00a0<\/span><\/h3>\n\t<div id=\"gap-468539545\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-468539545 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-235813064\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-235813064 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"none\">First-in-human trials in the U.S. can currently take up to 2 years to get started, according to the FDA [1]. That kind of lag has become a competitive issue, and regulators know it. Across this window, our Trends Radar tracked about 20 official developments on clinical trial speed, early development and expedited pathways in 8 jurisdictions, spanning North America, Europe, the Middle East and Latin America. The mechanisms differ, but the goal is the same: earlier engagement, fewer surprises and faster starts.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:300}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">The <\/span><b><span data-contrast=\"none\">FDA<\/span><\/b><span data-contrast=\"none\"> opened its Expedited IND Pilot, which pairs sponsors with qualified research institutions and tests rolling review during the pre-IND phase; it expects 8 to 10 pairs and accepts applications until 30 October 2026 [1]. It also opened year 5 of its CMC Development and Readiness Pilot for programs on accelerated clinical timelines [2] and launched a Rare Disease Framework Initiative, noting that only about 5% of rare conditions have an FDA-approved treatment [3]. In Europe, <\/span><b><span data-contrast=\"none\">EMA<\/span><\/b><span data-contrast=\"none\"> confirmed that its pre-submission advice pilot for clinical trial applications becomes permanent in January 2027 [4], while its Management Board flagged that the proposed Biotech Act would affect about 70% of current Clinical Trials Information System functionality, with first changes to the Clinical Trials Regulation possible in early 2028 [5]. The U.K.&#8217;s <\/span><b><span data-contrast=\"none\">MHRA<\/span><\/b><span data-contrast=\"none\"> committed to halve the initial assessment of qualifying Phase 1 trials to 14 days and cut premium scientific advice from 90 to 45 days [6]. <\/span><b><span data-contrast=\"none\">Saudi Arabia&#8217;s SFDA<\/span><\/b><span data-contrast=\"none\"> and the Saudi NIH launched 5 clinical trial initiatives, including a clinical trials reliance pathway [7], and <\/span><b><span data-contrast=\"none\">Brazil&#8217;s ANVISA<\/span><\/b><span data-contrast=\"none\"> invited up to 8 new-medicine projects, 6 of them prioritized for national developers, into a regulatory advice program in which the agreed trial design becomes binding [8].<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:300}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">For sponsors, the first trial site is becoming a strategic choice rather than a default. Jurisdictions are competing on speed, predictability or both, and some, like Brazil, explicitly prioritize local developers [8]. Early agreements also carry more weight later: ANVISA&#8217;s binding design commitments [8] and the FDA&#8217;s rolling pre-IND review [1] both reward sponsors that invest in early dialogue. Teams that compare pathways across markets before locking their development plan can start sooner and avoid redesigning trials midstream.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:300}\">\u00a0<\/span><\/p>\n<p aria-level=\"3\"><b><span data-contrast=\"none\">References<\/span><\/b><span data-ccp-props=\"{&quot;335559738&quot;:200,&quot;335559739&quot;:100}\">\u00a0<\/span><\/p>\n<ol>\n<li>\n<p><span data-contrast=\"none\">FDA launches Expedited IND Pilot, begins accepting applications (15 Sep 2026): <\/span><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-launches-expedited-ind-pilot-begins-accepting-applications\"><span data-contrast=\"none\">https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-launches-expedited-ind-pilot-begins-accepting-applications<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program (updated 18 Sep 2026): <\/span><a href=\"https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/chemistry-manufacturing-and-controls-development-and-readiness-pilot-cdrp-program\"><span data-contrast=\"none\">https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/chemistry-manufacturing-and-controls-development-and-readiness-pilot-cdrp-program<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">FDA launches Rare Disease Framework Initiative (14 Oct 2026): <\/span><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease\"><span data-contrast=\"none\">https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">EMA Clinical trial applications advice pilot becomes permanent (8 Oct 2026): <\/span><a href=\"https:\/\/www.ema.europa.eu\/en\/news\/clinical-trial-applications-advice-pilot-becomes-permanent\"><span data-contrast=\"none\">https:\/\/www.ema.europa.eu\/en\/news\/clinical-trial-applications-advice-pilot-becomes-permanent<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">EMA Management Board: highlights of September 2026 meeting (1 Oct 2026): <\/span><a href=\"https:\/\/www.ema.europa.eu\/en\/news\/ema-management-board-highlights-september-2026-meeting\"><span data-contrast=\"none\">https:\/\/www.ema.europa.eu\/en\/news\/ema-management-board-highlights-september-2026-meeting<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">MHRA 2030 strategy to modernise patient-centred regulation for the era of AI and personalised medicines (14 Oct 2026): <\/span><a href=\"https:\/\/www.gov.uk\/government\/news\/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines\"><span data-contrast=\"none\">https:\/\/www.gov.uk\/government\/news\/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">SFDA and Saudi NIH launch 5 initiatives to advance clinical trials (7 Oct 2026): <\/span><a href=\"https:\/\/www.sfda.gov.sa\/en\/news\/19734\"><span data-contrast=\"none\">https:\/\/www.sfda.gov.sa\/en\/news\/19734<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">ANVISA selects new-medicine projects for regulatory advice initiative, Call Notice No. 7\/2026 (24 Sep 2026): <\/span><a href=\"https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2026\/anvisa-seleciona-projetos-de-novos-medicamentos-para-iniciativa-de-aconselhamento-regulatorio\"><span data-contrast=\"none\">https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2026\/anvisa-seleciona-projetos-de-novos-medicamentos-para-iniciativa-de-aconselhamento-regulatorio<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<\/ol>\n\t<div id=\"gap-1735535512\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1735535512 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h3><span class=\"TextRun MacChromeBold SCXW26276911 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW26276911 BCX0\" data-ccp-parastyle=\"heading 1\">Regulators Close <\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW26276911 BCX0\" data-ccp-parastyle=\"heading 1\">In<\/span><span class=\"NormalTextRun SCXW26276911 BCX0\" data-ccp-parastyle=\"heading 1\"> on the Gray Market for Weight-Loss <\/span><\/span><span class=\"TextRun MacChromeBold SCXW26276911 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW26276911 BCX0\" data-ccp-parastyle=\"heading 1\">Peptides<\/span><\/span><span class=\"EOP Selected SCXW26276911 BCX0\" data-ccp-props=\"{&quot;335559739&quot;:140}\">\u00a0<\/span><\/h3>\n<p><span data-contrast=\"none\">Demand for GLP-1 medicines has created a parallel market: counterfeit pens, unregistered imports and investigational peptides sold online, often labeled &#8220;for research use only.&#8221; Between mid-September and mid-October 2026, that market drew a coordinated response. Our Trends Radar logged about 14 official actions on falsified and unapproved weight-loss peptides in 11 jurisdictions across 6 regions, one of the widest geographic footprints of any life sciences theme this month. The direction is unmistakable: from consumer warnings to bans, seizures and prosecutions.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:300}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Much of the activity centered on retatrutide, an investigational weight-loss peptide not approved anywhere. <\/span><b><span data-contrast=\"none\">Argentina&#8217;s ANMAT<\/span><\/b><span data-contrast=\"none\"> banned the use, sale, advertising and distribution of any product declaring it, including online sales [1], and <\/span><b><span data-contrast=\"none\">Brazil&#8217;s ANVISA<\/span><\/b><span data-contrast=\"none\"> reported seizing more than 1,000 irregular products at Rio&#8217;s Gale\u00e3o Airport, including 572 units of retatrutide and 347 of tirzepatide [2]. Australia&#8217;s <\/span><b><span data-contrast=\"none\">TGA<\/span><\/b><span data-contrast=\"none\"> found that a product sold as retatrutide actually contained undeclared semaglutide at about 8 times the approved level, following a serious adverse event [3], and began Federal Court proceedings over unlawful peptide advertising [4]. Singapore&#8217;s <\/span><b><span data-contrast=\"none\">HSA<\/span><\/b><span data-contrast=\"none\"> warned that retatrutide and cagrilintide bought online have been linked to reports of anaphylaxis [5], and <\/span><b><span data-contrast=\"none\">Saudi Arabia&#8217;s SFDA<\/span><\/b><span data-contrast=\"none\"> referred online sellers of unregistered peptides for prosecution, with penalties of up to SAR 5 million and 5 years&#8217; imprisonment [6]. In the U.K., <\/span><b><span data-contrast=\"none\">MHRA<\/span><\/b><span data-contrast=\"none\"> and police seized more than 12,000 fake retatrutide and tirzepatide pens worth about \u00a32 million [7], and in the U.S. an <\/span><b><span data-contrast=\"none\">FDA<\/span><\/b><span data-contrast=\"none\"> criminal investigation led to charges over counterfeit Ozempic sourced from China [8]. Regulators are also tightening the legitimate channel: ANVISA brought retained prescriptions, including GLP-1 receptor agonists, under electronic control from 30 September [9], and <\/span><b><span data-contrast=\"none\">South Africa&#8217;s SAHPRA<\/span><\/b><span data-contrast=\"none\"> issued its first guideline on the quality and clinical aspects of synthetic peptide medicines [10].<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:300}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">For manufacturers of authorized GLP-1 and peptide products, this is more than a brand-protection issue. Counterfeit and unapproved products generate adverse events that can reach safety databases and headlines under a genuine product&#8217;s name [3], and regulators increasingly expect companies to support enforcement with authentication and market intelligence. For telehealth providers, compounders, wellness brands and online marketplaces, the message is equally clear: peptides promoted for weight loss, muscle gain or skin care are being treated as medicines, and advertising them is now an enforcement priority [4][6]. Monitoring enforcement actions across markets is the fastest way to spot where the next ban or seizure is likely to land.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:300}\">\u00a0<\/span><\/p>\n<p aria-level=\"3\"><b><span data-contrast=\"none\">References<\/span><\/b><span data-ccp-props=\"{&quot;335559738&quot;:200,&quot;335559739&quot;:100}\">\u00a0<\/span><\/p>\n<ol>\n<li>\n<p><span data-contrast=\"none\">ANMAT prohibits products declaring retatrutide, Disposition 6140\/26 (24 Sep 2026): <\/span><a href=\"https:\/\/www.argentina.gob.ar\/noticias\/anmat-prohibe-productos-que-declaren-contener-retatrutide-o-retatrutida\"><span data-contrast=\"none\">https:\/\/www.argentina.gob.ar\/noticias\/anmat-prohibe-productos-que-declaren-contener-retatrutide-o-retatrutida<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">ANVISA More than 1,000 irregular products seized at Gale\u00e3o Airport (22 Sep 2026): <\/span><a href=\"https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2026\/mais-de-1000-produtos-irregulares-apreendidos-no-aeroporto-do-galeao\"><span data-contrast=\"none\">https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2026\/mais-de-1000-produtos-irregulares-apreendidos-no-aeroporto-do-galeao<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">TGA tests counterfeit retatrutide product following serious adverse event report (14 Sep 2026): <\/span><a href=\"https:\/\/www.tga.gov.au\/safety\/safety-monitoring-and-information\/safety-alerts\/tga-tests-counterfeit-retatrutide-product-following-serious-adverse-event-report\"><span data-contrast=\"none\">https:\/\/www.tga.gov.au\/safety\/safety-monitoring-and-information\/safety-alerts\/tga-tests-counterfeit-retatrutide-product-following-serious-adverse-event-report<\/span><\/a><span data-contrast=\"none\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">TGA Former company and directors behind BioV8 to face court for alleged unlawful advertising of peptides (28 Sep 2026): <\/span><a href=\"https:\/\/www.tga.gov.au\/news\/media-releases\/former-company-and-directors-behind-biov8-face-court-alleged-unlawful-advertising-peptides\"><span data-contrast=\"none\">https:\/\/www.tga.gov.au\/news\/media-releases\/former-company-and-directors-behind-biov8-face-court-alleged-unlawful-advertising-peptides<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">HSA Singapore Risks of obtaining prescription medicines and unapproved injectable peptides through unauthorised channels (25 Sep 2026): <\/span><a href=\"https:\/\/www.hsa.gov.sg\/announcements\/risks-of-obtaining-prescription-medicines-unauthorised-channels\/\"><span data-contrast=\"none\">https:\/\/www.hsa.gov.sg\/announcements\/risks-of-obtaining-prescription-medicines-unauthorised-channels\/<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">SFDA takes action against websites and online accounts marketing unregistered peptides (29 Sep 2026): <\/span><a href=\"https:\/\/www.sfda.gov.sa\/en\/news\/19668\"><span data-contrast=\"none\">https:\/\/www.sfda.gov.sa\/en\/news\/19668<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">MHRA Counterfeit weight loss pens worth \u00a32 million seized by MHRA and West Midlands Police (15 Oct 2026): <\/span><a href=\"https:\/\/www.gov.uk\/government\/news\/counterfeit-weight-loss-pens-worth-2-million-seized-by-mhra-and-west-mids-police\"><span data-contrast=\"none\">https:\/\/www.gov.uk\/government\/news\/counterfeit-weight-loss-pens-worth-2-million-seized-by-mhra-and-west-mids-police<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">FDA investigation leads to charges against two Indian nationals involved in transnational counterfeit drug distribution scheme (29 Sep 2026): <\/span><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-investigation-leads-charges-against-two-indian-nationals-involved-transnational-counterfeit-drug\"><span data-contrast=\"none\">https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-investigation-leads-charges-against-two-indian-nationals-involved-transnational-counterfeit-drug<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">ANVISA Start of new SNCR stage: what changes from 30 September (21 Sep 2026): <\/span><a href=\"https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2026\/inicio-de-nova-etapa-do-sncr-o-que-muda-a-partir-de-30-de-setembro\"><span data-contrast=\"none\">https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2026\/inicio-de-nova-etapa-do-sncr-o-que-muda-a-partir-de-30-de-setembro<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">SAHPRA Guideline on the Quality and Clinical Aspects of Synthetic Peptides, SAHPGL-CRO-04 v1 (13 Oct 2026): <\/span><a href=\"https:\/\/www.sahpra.org.za\/document\/guideline-on-the-quality-and-clinical-aspects-of-synthetic-peptides\/\"><span data-contrast=\"none\">https:\/\/www.sahpra.org.za\/document\/guideline-on-the-quality-and-clinical-aspects-of-synthetic-peptides\/<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<\/ol>\n<h3>Generative AI Gets Its First Device Rulebooks\u00a0<\/h3>\n\t<div id=\"gap-2094773488\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2094773488 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"none\">Software that keeps learning after it reaches the market has always strained device rules written for fixed products. Generative AI strains them further. Between mid-September and mid-October 2026, our Trends Radar tracked about 11 AI-device actions from regulators in Japan, the U.K., the U.S., Singapore, China and Taiwan, along with WHO and the international forum where device regulators coordinate. For the first time, several of them are drafting rules written specifically for adaptive and generative systems.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:300}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Japan&#8217;s <\/span><b><span data-contrast=\"none\">PMDA<\/span><\/b><span data-contrast=\"none\"> published draft review points for medical devices that use generative AI, open for comment until 17 March 2027 [1]. The <\/span><b><span data-contrast=\"none\">U.K. government<\/span><\/b><span data-contrast=\"none\"> accepted all 44 recommendations of the National Commission into the Regulation of AI in Healthcare: MHRA will publish draft guidance on managing changes to adaptive AI devices by December 2026, consult on how AI devices are qualified and classified in 2027, and select the first wave of its AI Airlock post-market sandbox in November [2]. <\/span><b><span data-contrast=\"none\">MHRA&#8217;s<\/span><\/b><span data-contrast=\"none\"> 2030 strategy adds a dedicated centre for AI and digital health [3]. In the U.S., the <\/span><b><span data-contrast=\"none\">FDA<\/span><\/b><span data-contrast=\"none\"> denied a petition to exempt radiology computer-aided detection, diagnosis and triage software from 510(k) clearance, keeping premarket review in place [4]. The <\/span><b><span data-contrast=\"none\">WHO<\/span><\/b><span data-contrast=\"none\"> added AI-based computer-aided detection software for tuberculosis screening to its prequalification program, its first digital health product class [5]. Singapore&#8217;s <\/span><b><span data-contrast=\"none\">HSA<\/span><\/b><span data-contrast=\"none\"> reported that IMDRF delivered an AI and machine learning technical framework for harmonized oversight of AI-enabled devices during Singapore&#8217;s chairmanship [6], and China&#8217;s <\/span><b><span data-contrast=\"none\">NMPA<\/span><\/b><span data-contrast=\"none\"> signed a letter of intent with MHRA that covers, among other areas, regulation of AI-enabled medical devices [7].<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:300}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">Two signals matter for device and software manufacturers. First, oversight is shifting to the full lifecycle: how a model changes after approval is becoming as important as how it performed at launch [2]. Second, regulators are not lowering premarket expectations to get there; the FDA&#8217;s 510(k) decision shows the bar stays in place even as new frameworks emerge [4]. WHO prequalification also opens a new route into procurement markets for AI tools that meet its bar [5]. With Japan&#8217;s comment window open until March [1] and MHRA guidance due by year-end [2], now is the moment to build change-management documentation and post-market performance monitoring into AI product plans, and to help shape the rules while they are still drafts.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:300}\">\u00a0<\/span><\/p>\n<p aria-level=\"3\"><b><span data-contrast=\"none\">References<\/span><\/b><span data-ccp-props=\"{&quot;335559738&quot;:200,&quot;335559739&quot;:100}\">\u00a0<\/span><\/p>\n<ol>\n<li>\n<p><span data-contrast=\"none\">PMDA Public comment on draft review points for medical devices using generative AI (18 Sep 2026): <\/span><a href=\"https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/about-reviews\/devices\/0058.html\"><span data-contrast=\"none\">https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/about-reviews\/devices\/0058.html<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">MHRA \/ UK Government: Government backs recommendations of NHS doctors-led AI Commission (6 Oct 2026): <\/span><a href=\"https:\/\/www.gov.uk\/government\/news\/government-backs-recommendations-of-nhs-doctors-led-ai-commission\"><span data-contrast=\"none\">https:\/\/www.gov.uk\/government\/news\/government-backs-recommendations-of-nhs-doctors-led-ai-commission<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">MHRA 2030 strategy to modernise patient-centred regulation for the era of AI and personalised medicines (14 Oct 2026): <\/span><a href=\"https:\/\/www.gov.uk\/government\/news\/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines\"><span data-contrast=\"none\">https:\/\/www.gov.uk\/government\/news\/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">FDA Final order, Exemption from Premarket Notification: radiology computer-aided detection and\/or diagnosis and triage software, petition denied (91 FR 58817, 17 Sep 2026): <\/span><a href=\"https:\/\/www.federalregister.gov\/documents\/2026\/09\/17\/2026-19074\/medical-devices-exemption-from-premarket-notification-radiology-computer-aided-detection-andor\"><span data-contrast=\"none\">https:\/\/www.federalregister.gov\/documents\/2026\/09\/17\/2026-19074\/medical-devices-exemption-from-premarket-notification-radiology-computer-aided-detection-andor<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">WHO announces expansion of prequalification programme for medical devices (25 Sep 2026): <\/span><a href=\"https:\/\/www.who.int\/news\/item\/25-09-2026-who-announces-expansion-of-prequalification-programme-for-medical-devices\"><span data-contrast=\"none\">https:\/\/www.who.int\/news\/item\/25-09-2026-who-announces-expansion-of-prequalification-programme-for-medical-devices<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">HSA extends partnerships to speed access to health innovations across key markets in Africa, Malaysia and Saudi Arabia (17 Sep 2026): <\/span><a href=\"https:\/\/www.hsa.gov.sg\/announcements\/hsa-extends-partnerships-speed-access\/\"><span data-contrast=\"none\">https:\/\/www.hsa.gov.sg\/announcements\/hsa-extends-partnerships-speed-access\/<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<li>\n<p><span data-contrast=\"none\">NMPA signs letter of intent for cooperation with UK\u2019s MHRA (30 Sep 2026): <\/span><a href=\"https:\/\/english.nmpa.gov.cn\/2026-09\/30\/c_1217123.htm\"><span data-contrast=\"none\">https:\/\/english.nmpa.gov.cn\/2026-09\/30\/c_1217123.htm<\/span><\/a><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:0,&quot;335551620&quot;:0,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<\/li>\n<\/ol>\n\n","protected":false},"excerpt":{"rendered":"<p>From mid-September to mid-October 2026, life sciences regulators made one thing plain: they are working to speed up legitimate innovation and shut down illegitimate supply at the same time. Our Trends Radar tracked official developments across all nine RegASK regions, and three trends stood out. First, regulators are racing to get clinical trials started sooner,&#8230;<\/p>","protected":false},"author":46,"featured_media":9715,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-11774","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.8 (Yoast SEO v28.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Life Sciences in October 2026: Faster Trials and AI<\/title>\n<meta name=\"description\" content=\"Explore the changes in life sciences in October 2026 regarding faster trials, fake peptides, and AI rulebooks.\" \/>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Life Sciences in October 2026: Faster Trials, Fake Peptides and AI Rulebooks\" \/>\n<meta property=\"og:description\" content=\"Explore the changes in life sciences in October 2026 regarding faster trials, fake peptides, and AI rulebooks.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/biowissenschaften-im-oktober-2026-schnellere-studien-gefalschte-peptide-und-ki-regelwerke\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-29T02:49:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-30T03:59:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Shaffa Renaningtyas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaffa Renaningtyas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\\\/\"},\"author\":{\"name\":\"Shaffa Renaningtyas\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/6d86c29c9123b2b67a3ea8e259cdb925\"},\"headline\":\"Life Sciences in October 2026: Faster Trials, Fake Pept&hellip;\",\"datePublished\":\"2026-10-29T02:49:49+00:00\",\"dateModified\":\"2026-10-30T03:59:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\\\/\"},\"wordCount\":1812,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png\",\"articleSection\":[\"Blogs\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\\\/\",\"name\":\"Life Sciences in October 2026: Faster Trials and AI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png\",\"datePublished\":\"2026-10-29T02:49:49+00:00\",\"dateModified\":\"2026-10-30T03:59:34+00:00\",\"description\":\"Explore the changes in life sciences in October 2026 regarding faster trials, fake peptides, and AI rulebooks.\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png\",\"width\":800,\"height\":600,\"caption\":\"Fda Launches Unified Adverse Event Monitoring System Aems Streamline Postmarket Safety Reporting\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Agentic AI Regulatory Intelligence Platform\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@RegASK\",\"https:\\\/\\\/www.crunchbase.com\\\/organization\\\/regask\",\"https:\\\/\\\/www.bloomberg.com\\\/profile\\\/company\\\/1691237D:SP\",\"https:\\\/\\\/pitchbook.com\\\/profiles\\\/company\\\/265004-02\",\"https:\\\/\\\/www.cbinsights.com\\\/company\\\/RegASK\",\"https:\\\/\\\/vimeo.com\\\/RegASK\"],\"legalName\":\"RegASK PTE. LTD.\",\"foundingDate\":\"2018\",\"slogan\":\"Empowering Smarter Regulatory Decisions\",\"description\":\"Agentic AI regulatory intelligence and workflow orchestration platform for Life Sciences and Consumer Products. RegASK combines vertical LLMs, multi-agent AI architecture, and a global community of 1,800+ subject matter experts to deliver regulatory horizon scanning, impact analysis, compliance workflow automation, and audit-ready outputs across 160+ countries.\",\"areaServed\":\"Worldwide\",\"founder\":{\"@type\":\"Person\",\"name\":\"Caroline Shleifer\",\"jobTitle\":\"Founder & CEO\"},\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"79 Science Park Drive, #06-01, Cintech IV\",\"addressLocality\":\"Singapore\",\"postalCode\":\"118264\",\"addressCountry\":\"SG\"},\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+65 6817 6290\",\"contactType\":\"customer service\",\"availableLanguage\":[\"English\",\"French\",\"Japanese\",\"Spanish\",\"Chinese\",\"German\"]},\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":50,\"maxValue\":100},\"knowsAbout\":[\"Regulatory Intelligence\",\"Regulatory Compliance\",\"Regulatory Affairs\",\"Workflow Orchestration\",\"Life Sciences Regulation\",\"Consumer Products Regulation\",\"AI-Driven Compliance\"],\"hasCertification\":[{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 42001:2023\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27001:2022\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27701\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27018:2019\"},{\"@type\":\"Certification\",\"name\":\"SOC 2 Type II\"}]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/6d86c29c9123b2b67a3ea8e259cdb925\",\"name\":\"Shaffa Renaningtyas\",\"sameAs\":[\"https:\\\/\\\/regask.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lebenswissenschaften im Oktober 2026: Schnellere Studien und KI","description":"Erfahren Sie mehr \u00fcber die Ver\u00e4nderungen in den Biowissenschaften im Oktober 2026 in Bezug auf schnellere Studien, gef\u00e4lschte Peptide und KI-Regelwerke.","robots":{"index":"noindex","follow":"follow"},"og_locale":"de_DE","og_type":"article","og_title":"Life Sciences in October 2026: Faster Trials, Fake Peptides and AI Rulebooks","og_description":"Explore the changes in life sciences in October 2026 regarding faster trials, fake peptides, and AI rulebooks.","og_url":"https:\/\/regask.com\/de\/biowissenschaften-im-oktober-2026-schnellere-studien-gefalschte-peptide-und-ki-regelwerke\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-10-29T02:49:49+00:00","article_modified_time":"2026-10-30T03:59:34+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png","type":"image\/png"}],"author":"Shaffa Renaningtyas","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Shaffa Renaningtyas","Est. reading time":"8\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/#article","isPartOf":{"@id":"https:\/\/regask.com\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/"},"author":{"name":"Shaffa Renaningtyas","@id":"https:\/\/regask.com\/#\/schema\/person\/6d86c29c9123b2b67a3ea8e259cdb925"},"headline":"Life Sciences in October 2026: Faster Trials, Fake Pept&hellip;","datePublished":"2026-10-29T02:49:49+00:00","dateModified":"2026-10-30T03:59:34+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/"},"wordCount":1812,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png","articleSection":["Blogs"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/","url":"https:\/\/regask.com\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/","name":"Lebenswissenschaften im Oktober 2026: Schnellere Studien und KI","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png","datePublished":"2026-10-29T02:49:49+00:00","dateModified":"2026-10-30T03:59:34+00:00","description":"Erfahren Sie mehr \u00fcber die Ver\u00e4nderungen in den Biowissenschaften im Oktober 2026 in Bezug auf schnellere Studien, gef\u00e4lschte Peptide und KI-Regelwerke.","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/life-sciences-in-october-2026-faster-trials-fake-peptides-and-ai-rulebooks\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/fda-launches-unified-adverse-event-monitoring-system-aems-streamline-postmarket-safety-reporting-1.png","width":800,"height":600,"caption":"Fda Launches Unified Adverse Event Monitoring System Aems Streamline Postmarket Safety Reporting"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Agentic KI-Plattform f\u00fcr regulatorische Intelligenz","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/@RegASK","https:\/\/www.crunchbase.com\/organization\/regask","https:\/\/www.bloomberg.com\/profile\/company\/1691237D:SP","https:\/\/pitchbook.com\/profiles\/company\/265004-02","https:\/\/www.cbinsights.com\/company\/RegASK","https:\/\/vimeo.com\/RegASK"],"legalName":"RegASK PTE. LTD.","foundingDate":"2018","slogan":"Empowering Smarter Regulatory Decisions","description":"Agentic AI ist eine Plattform f\u00fcr regulatorische Analysen und Workflow-Orchestrierung in den Bereichen Life Sciences und Konsumg\u00fcter. RegASK kombiniert vertikale LLMs, eine Multiagenten-KI-Architektur und eine globale Community von \u00fcber 1.800 Fachexperten, um regulatorische Zukunftsprognosen, Wirkungsanalysen, die Automatisierung von Compliance-Workflows und auditfertige Ergebnisse in \u00fcber 160 L\u00e4ndern bereitzustellen.","areaServed":"Worldwide","founder":{"@type":"Person","name":"Caroline Shleifer","jobTitle":"Founder & CEO"},"address":{"@type":"PostalAddress","streetAddress":"79 Science Park Drive, #06-01, Cintech IV","addressLocality":"Singapore","postalCode":"118264","addressCountry":"SG"},"contactPoint":{"@type":"ContactPoint","telephone":"+65 6817 6290","contactType":"customer service","availableLanguage":["English","French","Japanese","Spanish","Chinese","German"]},"numberOfEmployees":{"@type":"QuantitativeValue","minValue":50,"maxValue":100},"knowsAbout":["Regulatory Intelligence","Regulatory Compliance","Regulatory Affairs","Workflow Orchestration","Life Sciences Regulation","Consumer Products Regulation","AI-Driven Compliance"],"hasCertification":[{"@type":"Certification","name":"ISO\/IEC 42001:2023"},{"@type":"Certification","name":"ISO\/IEC 27001:2022"},{"@type":"Certification","name":"ISO\/IEC 27701"},{"@type":"Certification","name":"ISO\/IEC 27018:2019"},{"@type":"Certification","name":"SOC 2 Type II"}]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/6d86c29c9123b2b67a3ea8e259cdb925","name":"Shaffa Renaningtyas","sameAs":["https:\/\/regask.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/11774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/46"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=11774"}],"version-history":[{"count":4,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/11774\/revisions"}],"predecessor-version":[{"id":11830,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/11774\/revisions\/11830"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/9715"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=11774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=11774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=11774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}